Dr. Fernando Lecanda, the CIMA of Navarra, Santiago moved in some of the lines of his research on bone metastasis.

Dr. Lecanda Lamb rejoined in 2001 to the University of Navarre, after conducting postdoctoral Paris and Washington, where he currently directs the Laboratory of Adhesion and Metastasis in Oncology Division of the Center for Applied Medical Research (CIMA) . I3 Program is a research and interests focus on mechanisms of metastasis bone sarcoma and lung cancer, a topic covered in the Clinical Tuesday of The Rose Garden Foundation.


Most of the tumors metastasize in the bone and these metastases have poor survival. So said Dr. Lecanda, over 95% of those suffering from multiple myeloma bone metastases, and between 30 and 40% of those with lung cancer. And in this latter case, for example, bone metastasis is almost always fatal, probably because they are often detected before itself the initial tumor metastasis.

The spread of cancer cells from the primary tumor represents the most devastating consequence of cancer. “90% of deaths in patients with metastatic cancer are,” said the doctor just starting his presentation, during which he explained that a hallmark of metastasis is the “cell propensity to stay in selecting bodies like the skeleton” . So his lab seeks to understand how this process, “what makes a target bone as unique as bone microenvironment influences metastatic progression.”

This is another highly variable features that make the study of these conditions: that each case is different. “Sometimes cancer cells remain in the long primary tumor but not in others, most are detected before the target organ than in the primary,” said the doctor. Hence the difficulties in establishing effective treatments, virtually nonexistent in the case of metastases and especially important for affecting the bone, as they often lead to metabolic disorders, fractures and severe pain resistant to conventional analgesics. Hence the importance of knowing the process and know how to block or slow metastasis. Although there has been some progress in this aspect, the CIMA has been successful in lung tumors that metastasize to the bone, there is still much to learn.

Although not yet clear about the process, in both cases there is a similar route and pattern of spread to the lungs, causing the death phase. The efforts of the team led by Dr. Lecanda intended to identify key pathways induced early in the sarcomagenesis and functionally characterize the contribution in maintaining the tumorigenic and metastatic process.


In the CIMA study the mechanisms for the most common solid tumors in children and adolescents. Despite major therapeutic improvements and reduction in mortality, “survival in patients with osteosarcoma and Ewing sarcoma is very low especially before the onset of the metastatic process.” The conference was presented by Managing Director hospital’s Rose Garden Rafael Silva, who accompanied the coordinator of the cycle, Dr. Rafael Lopez, Chief of Medical Oncology, University Hospital of Santiago, and the Vice Chancellor for Research at the University of Santiago, Francisco Gonzalez.